• Profile
Close

Dulaglutide and renal outcomes in type 2 diabetes: An exploratory analysis of the REWIND randomized, placebo-controlled trial

The Lancet Jul 17, 2019

Gerstein HC, et al. - Through an exploratory analysis of the REWIND, a multicenter, randomized, double-blind, placebo-controlled trial at 371 sites in 24 countries, experts evaluated the long-term impact of the glucagon-like peptide-1 receptor agonist dulaglutide on renal outcome of the effect of dulaglutide on cardiovascular disease. A total of 9,901 people were recruited and randomly allotted to receive dulaglutide (n=4,949) or placebo (n=4,952). The renal outcome was produced in 848 participants at an incidence rate of 3.5 per 100 person-years in the dulaglutide group and in 970 participants at an incidence rate of 4.1 per 100 person-years in the placebo group, during a median follow-up of 5.4 years comprising 51,820 person-years. In people with type 2 diabetes, long-term use of dulaglutide was correlated with decreased composite renal outcomes.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay